Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
作者信息
Pacher Pál
出版信息
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):7-9. doi: 10.1161/ATVBAHA.108.178129.
Abstract
摘要
相似文献
1
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?用于治疗动脉粥样硬化和心脏代谢紊乱的大麻素CB1受体拮抗剂：新希望，旧担忧？
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):7-9. doi: 10.1161/ATVBAHA.108.178129.
2
Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?大麻素CB1受体拮抗剂利莫那班是否正在推动肥胖症的治疗？
Expert Opin Pharmacother. 2005 Oct;6(12):2141-4. doi: 10.1517/14656566.6.12.2141.
3
Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.利莫那班是一种选择性大麻素CB1受体拮抗剂，可抑制低密度脂蛋白受体缺陷小鼠的动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):12-8. doi: 10.1161/ATVBAHA.108.168757. Epub 2008 Oct 9.
4
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.使用大麻素CB1受体拮抗剂治疗代谢紊乱。
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):103-16. doi: 10.1016/j.beem.2008.09.001.
5
Rimonabant and progression of atherosclerosis in obese persons.利莫那班与肥胖人群动脉粥样硬化的进展
JAMA. 2008 Jul 16;300(3):280; author reply 280-1. doi: 10.1001/jama.2008.24.
6
STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
Cardiovasc J Afr. 2008 May-Jun;19(3):158-9.
7
[Pharmacology of cannabinoid receptors].[大麻素受体的药理学]
Bull Acad Natl Med. 2007 Apr-May;191(4-5):933-8; discussion 938-40.
8
Rimonabant, obesity and diabetes.利莫那班、肥胖与糖尿病。
Prescrire Int. 2007 Jun;16(89):122.
9
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.CB1受体阻断及其对心脏代谢危险因素的影响：使用利莫那班的RIO项目综述
J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x.
10
The psychiatric side-effects of rimonabant.利莫那班的精神副作用。
Braz J Psychiatry. 2009 Jun;31(2):145-53. doi: 10.1590/s1516-44462009000200012.
引用本文的文献
1
Role of CB1 Cannabinoid Receptors in Vascular Responses and Vascular Remodeling of the Aorta in Female Mice.CB1 cannabinoid 受体在雌性小鼠主动脉血管反应和血管重塑中的作用。
Int J Mol Sci. 2023 Nov 17;24(22):16429. doi: 10.3390/ijms242216429.
2
Epigenetic Studies for Evaluation of NPS Toxicity: Focus on Synthetic Cannabinoids and Cathinones.用于评估新型精神活性物质毒性的表观遗传学研究：聚焦合成大麻素和卡西酮
Biomedicines. 2022 Jun 13;10(6):1398. doi: 10.3390/biomedicines10061398.
3
ZnO Nanoparticles Induce Dyslipidemia and Atherosclerotic Lesions Leading to Changes in Vascular Contractility and Cannabinoid Receptors Expression as Well as Increased Blood Pressure.氧化锌纳米颗粒可引发血脂异常和动脉粥样硬化病变，导致血管收缩性和大麻素受体表达发生变化，并使血压升高。
Nanomaterials (Basel). 2021 Sep 7;11(9):2319. doi: 10.3390/nano11092319.
4
Occurrence of Takotsubo Cardiomyopathy after Synthetic Cannabinoid Consumption.使用合成大麻素后发生应激性心肌病
Addict Health. 2019 Jul;11(3):202-206. doi: 10.22122/ahj.v11i3.239.
5
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.大麻和合成大麻素对心血管的影响：有好有坏，也有丑。
Nat Rev Cardiol. 2018 Mar;15(3):151-166. doi: 10.1038/nrcardio.2017.130. Epub 2017 Sep 14.
6
Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?饮食中的类大麻素植物化学物质——与食物选择和代谢应激适应的进化联系？
Br J Pharmacol. 2017 Jun;174(11):1464-1483. doi: 10.1111/bph.13676. Epub 2017 Jan 16.
7
Newer antiatherosclerosis treatment strategies.新型抗动脉粥样硬化治疗策略。
Heart Asia. 2011 Jan 1;3(1):26-30. doi: 10.1136/ha.2010.003129. eCollection 2011.
8
Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages.GPR55受体的激活会加剧氧化型低密度脂蛋白（oxLDL）诱导的脂质积累和炎症反应，同时减少人巨噬细胞的胆固醇流出。
PLoS One. 2015 May 13;10(5):e0126839. doi: 10.1371/journal.pone.0126839. eCollection 2015.
9
Cannabis smoking and serum C-reactive protein: a quantile regressions approach based on NHANES 2005-2010.吸食大麻与血清C反应蛋白：基于2005 - 2010年美国国家健康与营养检查调查（NHANES）的分位数回归方法
Drug Alcohol Depend. 2015 Feb 1;147:203-7. doi: 10.1016/j.drugalcdep.2014.11.017. Epub 2014 Nov 28.
10
Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation.内源性大麻素受体 CB1 的激活促进血管平滑肌细胞增殖和新生内膜形成。
J Lipid Res. 2013 May;54(5):1360-8. doi: 10.1194/jlr.M035147. Epub 2013 Mar 11.
本文引用的文献
1
Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation.大麻素CB1受体抑制可减少血管平滑肌迁移和增殖。
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1248-52. doi: 10.1016/j.bbrc.2008.10.159. Epub 2008 Nov 6.
2
Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.利莫那班是一种选择性大麻素CB1受体拮抗剂，可抑制低密度脂蛋白受体缺陷小鼠的动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):12-8. doi: 10.1161/ATVBAHA.108.168757. Epub 2008 Oct 9.
3
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models.白细胞亚群对动脉粥样硬化的多方面贡献：来自小鼠模型的经验教训。
Nat Rev Immunol. 2008 Oct;8(10):802-15. doi: 10.1038/nri2415.
4
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.心血管疾病中内源性大麻素系统的调节：治疗潜力与局限性
Hypertension. 2008 Oct;52(4):601-7. doi: 10.1161/HYPERTENSIONAHA.105.063651. Epub 2008 Sep 8.
5
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.小夜曲研究：评估利莫那班在初治糖尿病患者中的疗效：首个选择性CB1受体拮抗剂利莫那班单药治疗对初治2型糖尿病患者血糖控制、体重和血脂谱的影响
Diabetes Care. 2008 Nov;31(11):2169-76. doi: 10.2337/dc08-0386. Epub 2008 Aug 4.
6
The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats.大麻素受体-1拮抗剂利莫那班可抑制血小板活化，并减少Zucker大鼠体内的促炎趋化因子和白细胞。
Br J Pharmacol. 2008 Jul;154(5):1047-54. doi: 10.1038/bjp.2008.158. Epub 2008 May 12.
7
Targeting the endocannabinoid system: to enhance or reduce?靶向内源性大麻素系统：增强还是降低？
Nat Rev Drug Discov. 2008 May;7(5):438-55. doi: 10.1038/nrd2553.
8
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.利莫那班阻断CB1对心脏代谢危险因素的长期影响：欧洲RIO研究的两年结果
Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15.
9
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.利莫那班对腹型肥胖合并冠状动脉疾病患者动脉粥样硬化进展的影响：STRADIVARIUS随机对照试验
JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.
10
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.利莫那班改善超重/肥胖患者多种心血管代谢危险因素的疗效和安全性：来自肥胖症利莫那班（RIO）项目的1年汇总数据。
Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258.
Zotero 插件